Sirio Pharma Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Sirio Pharma Co., Ltd. carries a market capitalization of 4.92B, placing it among publicly traded companies globally. Its enterprise value stands at 7.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.92B |
| Enterprise Value | 7.34B |
Share Statistics
Sirio Pharma Co., Ltd. currently has 307.63M shares outstanding.
| Shares Outstanding | 307.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Sirio Pharma Co., Ltd. trades at a trailing price-to-earnings ratio of 332.23. The price-to-sales ratio is 2.02, and the price-to-book ratio stands at 3.37.
| PE Ratio | 332.23 |
| PS Ratio | 2.02 |
| PB Ratio | 3.37 |
| P/TBV Ratio | 3.01 |
| P/FCF Ratio | 20.85 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Sirio Pharma Co., Ltd. trades at an EV/EBITDA multiple of 37.01 and an EV/FCF ratio of 20.45. The EV/Sales ratio of 2.40 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 37.01 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.40 |
| EV / EBITDA | 37.01 |
| EV / EBIT | 37.01 |
| EV / FCF | 20.45 |
Financial Position
Sirio Pharma Co., Ltd. maintains a current ratio of 1.85, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.99, indicating elevated leverage, while an interest coverage ratio of 2.03 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.85 |
| Quick Ratio | 0.61 |
| Debt / Equity | 60.99 |
| Debt / EBITDA | 9.12 |
| Interest Coverage | 2.03 |
Financial Efficiency
| Return on Equity (ROE) | 1.02 |
| Return on Assets (ROA) | 0.33 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 20.15 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.23 |
Taxes
Over the trailing twelve months, Sirio Pharma Co., Ltd. has paid -45.64M in income taxes, reflecting an effective tax rate of 23.72.
| Income Tax | -45.64M |
| Effective Tax Rate | 23.72 |
Stock Price Statistics
Sirio Pharma Co., Ltd.'s stock has declined approximately -30.21016% over the past 52 weeks. The 50-day moving average sits at 17.68, while the 200-day moving average is 21.57.
| Beta (5Y) | N/A |
| 52-Week Price Change | -30.21016% |
| 50-Day Moving Average | 17.68 |
| 200-Day Moving Average | 21.57 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Sirio Pharma Co., Ltd. generated 3.06B in revenue and converted that into 18.65M in net income, yielding earnings per share of -0.26. EBITDA reached 198.42M, while operating income came in at 198.42M.
| Revenue | 3.06B |
| Gross Profit | 927.92M |
| Operating Income | 198.42M |
| Pretax Income | -125.37M |
| Net Income | 18.65M |
| EBITDA | 198.42M |
| EBIT | 198.42M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
Sirio Pharma Co., Ltd. holds 669.31M in cash and equivalents against 1.81B in total debt, resulting in a net debt position of 759.94M. Total book value stands at 1.84B, with working capital of 921.58M providing operational flexibility.
| Cash & Cash Equivalents | 669.31M |
| Total Debt | 1.81B |
| Net Debt | 759.94M |
| Equity (Book Value) | 1.84B |
| Book Value Per Share | 6.03 |
| Working Capital | 921.58M |
Cash Flow
After subtracting -297.11M in capital expenditures, free cash flow totaled -297.11M - equivalent to -0.97 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -297.11M |
| Free Cash Flow | -297.11M |
| FCF Per Share | -0.97 |
Margins
Sirio Pharma Co., Ltd. operates with a gross margin of 30.30, reflecting its pricing power and cost economics. The operating margin of 6.48 and net profit margin of 0.61 provide insight into operational efficiency.
| Gross Margin | 30.30 |
| Operating Margin | 6.48 |
| Pretax Margin | -4.09 |
| Profit Margin | 0.61 |
| EBITDA Margin | 6.48 |
Dividends & Yields
The company's payout ratio of -101.12 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.59 |
| Dividend Yield | N/A |
| Payout Ratio | -101.12 |
| Shareholder Yield | -2.04 |
| FCF Yield | 4.80 |
Stock Splits
Sirio Pharma Co., Ltd.'s most recent stock split took place on June 21, 2024 with a 10:13 split ratio.
| Last Split Date | 6/21/2024 |
| Split Ratio | 10:13 |
Scores
Sirio Pharma Co., Ltd. posts an Altman Z-Score of 2.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.80 |